RESUMEN
Understanding the impact of the COVID-19 pandemic on systemic anticancer therapy delivery (SACT) is crucial to appreciate the short- and long-term consequences for cancer patients and plan future care. Here, we report real-time national SACT delivery data from NHS Scotland. We demonstrate an initial rapid reduction in patient attendance of 28.7% with subsequent rapid recovery following service redesign. The smallest decrease was seen in breast cancer (19.7%), which also had the most rapid recovery and the largest decrease seen in colorectal cancer (43.4%). Regional variation in the magnitude of impact on SACT delivery was observed, but nadirs occurred at the same time and the rate of recovery was similar across all regions. This recovery reflected a coordinated national approach and associated patient and clinician support structures, which facilitated the creation of COVID-19-protected areas for SACT delivery in Scottish cancer centres enabling rapid sharing of successful and innovative strategies. The data show that these actions have limited the disadvantage to cancer patients.
Asunto(s)
COVID-19/terapia , Neoplasias Colorrectales/terapia , Pandemias , COVID-19/complicaciones , COVID-19/epidemiología , COVID-19/virología , Neoplasias Colorrectales/complicaciones , Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/virología , Femenino , Humanos , Masculino , SARS-CoV-2/genética , SARS-CoV-2/patogenicidad , Escocia/epidemiologíaRESUMEN
Breast cancer is the most frequently diagnosed malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. To assist women who are at increased risk of developing breast cancer and their physicians in the application of individualized strategies to reduce breast cancer risk, NCCN has developed these guidelines for breast cancer risk reduction.
Asunto(s)
Neoplasias de la Mama/prevención & control , Conducta de Reducción del Riesgo , Femenino , Humanos , Factores de RiesgoAsunto(s)
Trastorno Depresivo/psicología , Matrimonio/psicología , Adulto , Antidepresivos de Segunda Generación/uso terapéutico , Antipsicóticos/uso terapéutico , Cultura , Trastorno Depresivo/tratamiento farmacológico , Femenino , Humanos , Visita a Consultorio Médico , Paroxetina/uso terapéutico , Embarazo/psicología , Apoyo Social , Trifluoperazina/uso terapéuticoRESUMEN
Social phobia is prevalent during adolescence and is associated with negative outcomes. Two self-report instruments are empirically validated to specifically assess social phobia symptomatology in youth: the Social Phobia and Anxiety Inventory for Children and the Social Anxiety Scale for Adolescents. The Multidimensional Anxiety Scale for Children is a broad-band measure of anxiety containing a scale assessing the social phobia construct. The present study investigated the MASC Social Anxiety Scale in relation to other well-established measures of social phobia and depression in a non-referred sample of adolescents. Results support the convergent validity of the MASC Social Anxiety Scale and provide some support for its discriminant validity, suggesting its utility in the initial assessment of social phobia. Receiver Operating Characteristics (ROCs) calculated the sensitivity and specificity of the MASC Social Anxiety Scale. Binary logistic regression analyses determined the predictive utility of the MASC Social Anxiety Scale. Implications for assessment are discussed.